Re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer.
2016-01-01 Conteduca, V; Lolli, C; De Giorgi, U
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: A Retrospective International Study of Invasive/advanced cancer of the urothelium (RISC).
2018-01-01 Bamias, A; Tzannis, K; Harshman, Lc; Crabb, Sj; Wong, Yn; Pal, Sk; De Giorgi, U; Ladoire, S; Agarwal, N; Yu, Ey; Niegisch, G; Necchi, A; Sternberg, Cn; Srinivas, S; Alva, A; Vaishampayan, U; Cerbone, L; Liontos, M; Rosenberg, J; Powles, T; Belmunt, J; Galsky, Md
A sequential chemo-radiotherapeutic treatment for patients with malignant gliomas: a phase II pilot study
2000-01-01 Dazzi, C; Cariello, A; Giannini, M; Del Duca, M; Giovanis, P; Fiorentini, G; Leoni, M; Rosti, G; Turci, D; Tienghi, A; Vertogen, B; Zumaglini, F; De Giorgi, U; Marangolo, M
Tyrosine kinase inhibitor imatinib mesylate as anticancer agent for advanced ocular melanoma expressing immunoistochemical C-KIT (CD 117): preliminary results of a compassionate use clinical trial
2003-01-01 Fiorentini, G; Rossi, S; Lanzanova, G; Biancalani, M; Palomba, A; Bernardeschi, P; Dentico, P; De Giorgi, U
Taxane-related nail toxicity
2015-01-01 Schepisi, G; Conteduca, V; Lolli, C; Medri, M; De Giorgi, U
The status of high-dose chemotherapy with hematopoietic stem cell transplantation in germ cell tumor patients
2002-01-01 De Giorgi, U; Rosti, G; Papiani, G; Marangolo, M.
Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma
2016-01-01 Farolfi, A; Schepisi, G; Conteduca, V; Burgio, Sl; Lolli, C; De Giorgi, U
Psychosocial issues in long-term survivors of testicular cancer
2019-01-01 Schepisi, G.; De Padova, S.; De Lisi, D.; Casadei, C.; Meggiolaro, E.; Ruffilli, F.; Rosti, G.; Lolli, C.; Ravaglia, G.; Conteduca, V.; Farolfi, A.; Grassi, L.; De Giorgi, U.
Recruiting long-term survivors of European Organisation for Research and Treatment of Cancer phase III clinical trials into quality of life studies: challenges and opportunities
2014-01-01 Van Leeuwen, M; Efficace, F; Fosså, Sd; Bolla, M; De Giorgi, U; de Wit, R; Holzner, B; van de Poll-Franse, Lv; van Poppel, H; White, J; Collette, L; Osanto, S; Aaronson, Nk
Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma
2016-01-01 Santini, D; Santoni, M; Conti, A; Procopio, G; Verzoni, E; Galli, L; di Lorenzo, G; De Giorgi, U; De Lisi, D; Nicodemo, M; Maruzzo, M; Massari, F; Buti, S; Altobelli, E; Biasco, E; Ricotta, R; Porta, C; Vincenzi, B; Papalia, R; Marchetti, P; Burattini, L; Berardi, R; Muto, G; Montironi, R; Cascinu, S; Tonini, G
Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer
2016-01-01 Mego, M; Gao, H; Cohen, En; Anfossi, S; Giordano, A; Sanda, T; Fouad, Tm; De Giorgi, U; Giuliano, M; Woodward, Wa; Alvarez, Rh; Valero, V; Ueno, Nt; Hortobagyi, Gn; Cristofanilli, M; Reuben, Jm
Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer
2009-01-01 De Giorgi, U; Valero, V; Rohren, E; Dawood, S; Ueno, Nt; Miller, Mc; Doyle, Gv; Jackson, S; Andreopoulou, E; Handy, Bc; Reuben, Jm; Fritsche, Ha; Macapinlac, Ha; Hortobagyi, Gn; Cristofanilli, M.
Pazopanib versus sunitinib in metastatic renal-cell carcinoma
2013-01-01 Motzer, Rj; Hutson, Te; Cella, D; Reeves, J; Hawkins, R; Guo, J; Nathan, P; Staehler, M; de Souza, P; Merchan, Jr; Boleti, E; Fife, K; Jin, J; Jones, R; Uemura, H; De Giorgi, U; Harmenberg, U; Wang, J; Sternberg, Cn; Deen, K; Mccann, L; Hackshaw, Md; Crescenzo, R; Pandite, Ln; Choueiri, Tk
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer
2017-01-01 Iacovelli, R; Cossu Rocca, M; Galli, L; De Giorgi, U; Sabbatini, R; Santoni, M; Mosca, A; Fornarini, G; Massari, F; Masini, C; Bersanelli, M; Biasco, E; Lolli, C; Guida, A; Berardi, R; Terrone, C; Pastorino, A; Ardizzoni, A; Pinto, C; Buti, S; Nolè, F; Tortora, G
Clinical impact of pancreatic metastases from renal cell carcinoma: A multicenter retrospective analysis
2016-01-01 Grassi, P; Doucet, L; Giglione, P; Grünwald, V; Melichar, B; Galli, L; De Giorgi, U; Sabbatini, R; Ortega, C; Santoni, M; Bamias, A; Verzoni, E; Derosa, L; Studentova, H; Pacifici, M; Coppa, J; Mazzaferro, V; de Braud, F; Porta, C; Escudier, B; Procopio, G.
Immune system and DNA repair defects in ovarian cancer: Implications for locoregional approaches
2019-01-01 Farolfi, A.; Gurioli, G.; Fugazzola, P.; Burgio, S. L.; Casanova, C.; Ravaglia, G.; Altavilla, A.; Costantini, M.; Amadori, A.; Framarini, M.; Ansaloni, L.; De Giorgi, U.
Plasma androgen receptor and serum chromogranin A in advanced prostate cancer
2018-01-01 Conteduca, V.; Scarpi, E.; Salvi, S.; Casadio, V.; Lolli, C.; Gurioli, G.; Schepisi, G.; Wetterskog, D.; Farolfi, A.; Menna, C.; De Lisi, D.; Burgio, S. L.; Beltran, H.; Attard, G.; De Giorgi, U.
Dose intensification in hormone receptor–negative and/or human epidermal growth factor receptor 2–negative high-risk primary breast cancer.
2012-01-01 De Giorgi, U; Amadori, D.
Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors
2015-01-01 Santoni, M; Conti, A; Partelli, S; Porta, C; Sternberg, Cn; Procopio, G; Bracarda, S; Basso, U; De Giorgi, U; Derosa, L; Rizzo, M; Ortega, C; Massari, F; Iacovelli, R; Milella, M; Di Lorenzo, G; Buti, S; Cerbone, L; Burattini, L; Montironi, R; Santini, D; Falconi, M; Cascinu, S
Impact of Candidate Genetic Polymorphisms in Prostate Cancer: An Overview
2016-01-01 Salvi, S; Conteduca, V; Gurioli, G; Calistri, D; Casadio, V; De Giorgi, U
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. | 1-gen-2016 | Conteduca, V; Lolli, C; De Giorgi, U | |
| Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: A Retrospective International Study of Invasive/advanced cancer of the urothelium (RISC). | 1-gen-2018 | Bamias, A; Tzannis, K; Harshman, Lc; Crabb, Sj; Wong, Yn; Pal, Sk; De Giorgi, U; Ladoire, S; Agarwal, N; Yu, Ey; Niegisch, G; Necchi, A; Sternberg, Cn; Srinivas, S; Alva, A; Vaishampayan, U; Cerbone, L; Liontos, M; Rosenberg, J; Powles, T; Belmunt, J; Galsky, Md | |
| A sequential chemo-radiotherapeutic treatment for patients with malignant gliomas: a phase II pilot study | 1-gen-2000 | Dazzi, C; Cariello, A; Giannini, M; Del Duca, M; Giovanis, P; Fiorentini, G; Leoni, M; Rosti, G; Turci, D; Tienghi, A; Vertogen, B; Zumaglini, F; De Giorgi, U; Marangolo, M | |
| Tyrosine kinase inhibitor imatinib mesylate as anticancer agent for advanced ocular melanoma expressing immunoistochemical C-KIT (CD 117): preliminary results of a compassionate use clinical trial | 1-gen-2003 | Fiorentini, G; Rossi, S; Lanzanova, G; Biancalani, M; Palomba, A; Bernardeschi, P; Dentico, P; De Giorgi, U | |
| Taxane-related nail toxicity | 1-gen-2015 | Schepisi, G; Conteduca, V; Lolli, C; Medri, M; De Giorgi, U | |
| The status of high-dose chemotherapy with hematopoietic stem cell transplantation in germ cell tumor patients | 1-gen-2002 | De Giorgi, U; Rosti, G; Papiani, G; Marangolo, M. | |
| Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma | 1-gen-2016 | Farolfi, A; Schepisi, G; Conteduca, V; Burgio, Sl; Lolli, C; De Giorgi, U | |
| Psychosocial issues in long-term survivors of testicular cancer | 1-gen-2019 | Schepisi, G.; De Padova, S.; De Lisi, D.; Casadei, C.; Meggiolaro, E.; Ruffilli, F.; Rosti, G.; Lolli, C.; Ravaglia, G.; Conteduca, V.; Farolfi, A.; Grassi, L.; De Giorgi, U. | |
| Recruiting long-term survivors of European Organisation for Research and Treatment of Cancer phase III clinical trials into quality of life studies: challenges and opportunities | 1-gen-2014 | Van Leeuwen, M; Efficace, F; Fosså, Sd; Bolla, M; De Giorgi, U; de Wit, R; Holzner, B; van de Poll-Franse, Lv; van Poppel, H; White, J; Collette, L; Osanto, S; Aaronson, Nk | |
| Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma | 1-gen-2016 | Santini, D; Santoni, M; Conti, A; Procopio, G; Verzoni, E; Galli, L; di Lorenzo, G; De Giorgi, U; De Lisi, D; Nicodemo, M; Maruzzo, M; Massari, F; Buti, S; Altobelli, E; Biasco, E; Ricotta, R; Porta, C; Vincenzi, B; Papalia, R; Marchetti, P; Burattini, L; Berardi, R; Muto, G; Montironi, R; Cascinu, S; Tonini, G | |
| Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer | 1-gen-2016 | Mego, M; Gao, H; Cohen, En; Anfossi, S; Giordano, A; Sanda, T; Fouad, Tm; De Giorgi, U; Giuliano, M; Woodward, Wa; Alvarez, Rh; Valero, V; Ueno, Nt; Hortobagyi, Gn; Cristofanilli, M; Reuben, Jm | |
| Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer | 1-gen-2009 | De Giorgi, U; Valero, V; Rohren, E; Dawood, S; Ueno, Nt; Miller, Mc; Doyle, Gv; Jackson, S; Andreopoulou, E; Handy, Bc; Reuben, Jm; Fritsche, Ha; Macapinlac, Ha; Hortobagyi, Gn; Cristofanilli, M. | |
| Pazopanib versus sunitinib in metastatic renal-cell carcinoma | 1-gen-2013 | Motzer, Rj; Hutson, Te; Cella, D; Reeves, J; Hawkins, R; Guo, J; Nathan, P; Staehler, M; de Souza, P; Merchan, Jr; Boleti, E; Fife, K; Jin, J; Jones, R; Uemura, H; De Giorgi, U; Harmenberg, U; Wang, J; Sternberg, Cn; Deen, K; Mccann, L; Hackshaw, Md; Crescenzo, R; Pandite, Ln; Choueiri, Tk | |
| Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer | 1-gen-2017 | Iacovelli, R; Cossu Rocca, M; Galli, L; De Giorgi, U; Sabbatini, R; Santoni, M; Mosca, A; Fornarini, G; Massari, F; Masini, C; Bersanelli, M; Biasco, E; Lolli, C; Guida, A; Berardi, R; Terrone, C; Pastorino, A; Ardizzoni, A; Pinto, C; Buti, S; Nolè, F; Tortora, G | |
| Clinical impact of pancreatic metastases from renal cell carcinoma: A multicenter retrospective analysis | 1-gen-2016 | Grassi, P; Doucet, L; Giglione, P; Grünwald, V; Melichar, B; Galli, L; De Giorgi, U; Sabbatini, R; Ortega, C; Santoni, M; Bamias, A; Verzoni, E; Derosa, L; Studentova, H; Pacifici, M; Coppa, J; Mazzaferro, V; de Braud, F; Porta, C; Escudier, B; Procopio, G. | |
| Immune system and DNA repair defects in ovarian cancer: Implications for locoregional approaches | 1-gen-2019 | Farolfi, A.; Gurioli, G.; Fugazzola, P.; Burgio, S. L.; Casanova, C.; Ravaglia, G.; Altavilla, A.; Costantini, M.; Amadori, A.; Framarini, M.; Ansaloni, L.; De Giorgi, U. | |
| Plasma androgen receptor and serum chromogranin A in advanced prostate cancer | 1-gen-2018 | Conteduca, V.; Scarpi, E.; Salvi, S.; Casadio, V.; Lolli, C.; Gurioli, G.; Schepisi, G.; Wetterskog, D.; Farolfi, A.; Menna, C.; De Lisi, D.; Burgio, S. L.; Beltran, H.; Attard, G.; De Giorgi, U. | |
| Dose intensification in hormone receptor–negative and/or human epidermal growth factor receptor 2–negative high-risk primary breast cancer. | 1-gen-2012 | De Giorgi, U; Amadori, D. | |
| Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors | 1-gen-2015 | Santoni, M; Conti, A; Partelli, S; Porta, C; Sternberg, Cn; Procopio, G; Bracarda, S; Basso, U; De Giorgi, U; Derosa, L; Rizzo, M; Ortega, C; Massari, F; Iacovelli, R; Milella, M; Di Lorenzo, G; Buti, S; Cerbone, L; Burattini, L; Montironi, R; Santini, D; Falconi, M; Cascinu, S | |
| Impact of Candidate Genetic Polymorphisms in Prostate Cancer: An Overview | 1-gen-2016 | Salvi, S; Conteduca, V; Gurioli, G; Calistri, D; Casadio, V; De Giorgi, U |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Scopri
Tipologia
- 03 Articolo su Rivista38605
Data di pubblicazione
- In corso di stampa43
- 2020 - 202710433
- 2010 - 201913552
- 2000 - 20098692
- 1990 - 19993962
- 1980 - 19891442
- 1970 - 1979447
- 1961 - 196934
Editore
- Elsevier BV:PO Box 211, 1000 AE A...454
- American Institute of Physics:2 H...272
- Giuffre Editore Spa:via Busto Ars...128
- Elsevier Science Limited:Oxford F...99
- Congedo Editore Luogo pubbl. Gal...72
- IOP Publishing Limited:Dirac Hous...71
- Springer Verlag Germany:Tiergarte...71
- Kluwer Academic Publishers:Journa...54
- IEEE / Institute of Electrical an...47
- Societa Editrice il Mulino Spa:St...43
Rivista
- JOURNAL OF HIGH ENERGY PHYSICS481
- THE EUROPEAN PHYSICAL JOURNAL. C,...393
- PHYSICS LETTERS. SECTION B392
- PHYSICAL REVIEW LETTERS211
- APPLIED PHYSICS LETTERS186
- NUCLEAR INSTRUMENTS AND METHODS I...185
- THE ASTROPHYSICAL JOURNAL180
- PHYSICAL REVIEW D, PARTICLES, FIE...156
- PHYSICAL REVIEW D148
- ITINERARI DI RICERCA STORICA140
Keyword
- ATLAS1158
- LHC1151
- High Energy Physics1130
- Humans376
- Mediterranean Sea185
- Italy177
- Female144
- Animals143
- Male127
- Hadron-Hadron Scattering122
Lingua
- eng25985
- ita9002
- fre415
- spa191
- ger146
- por94
- lat51
- grc47
- rus43
- chi13
Accesso al fulltext
- no fulltext32279
- open4081
- restricted1185
- reserved1012
- partially open32
- mixed10
- embargoed6